Sort
21,281 grants matching “influenza”
PREPAREDNESS AND RESPONSE TO AVIAN AND PANDEMIC INFLUENZA IN MADAGASCAR
$500,000Jean-Michel Heraud · Pasteur Institute From Madagascar · U51 · FY2010 · IP
Dose Optimization, Production & Tox Testing of Replicon-Vaccines for Smallpox
$500,000Kurt I Kamrud · Alphavax Human Vaccines, Inc. · U01 · FY2008 · AI
Monitoring cause-specific school absences to estimate influenza transmission in W
$500,000Derek A Cummings · Johns Hopkins University · U01 · FY2014 · CK
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.
$500,000Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2019 · IP
Microchip for HBV testing using HIV-infected blood samples
$500,000Hadi Shafiee · Brigham And Women'S Hospital · R01 · FY2023 · AI
Study of Influenza Incidence, Diagnosis, Treatment Efficacy, Vaccine Effectivenes
$500,000Nestor Sosa · Gorgas Memorial Institute Of Health St · U01 · FY2015 · IP
DEVELOPMENT OF INFLUENZA SURVEILLANCE NETWORKS
$500,000Yuelong Shu · Natl Inst Of Viral Disease Control/Prev · U50 · FY2007 · CI
Vaccine and Treatment Evaluation Units
$500,000Wendy A Keitel · Baylor College Of Medicine · N01 · FY2012 · AI
A massively parallel DNA sequencer
$500,000James E Goldman · Columbia University Health Sciences · S10 · FY2008 · RR
Development of a DNA Vaccine Against Influenza Virus
$500,000Vical, Inc. · R43 · FY2005 · AI
Immune Function and Biodefense in Children, Elderly, and the Immunocrompromised
$500,000University Of Rochester · N01 · FY2009 · AI
Ecology of Infectious Diseases (EID)-Immune Landscapes of Human Influenza in Hous
$500,000Derek A Cummings · Johns Hopkins University · R01 · FY2008 · TW
Ecology of Infectious Diseases (EID)-Immune Landscapes of Human Influenza in Hous
$500,000Derek A Cummings · Johns Hopkins University · R01 · FY2009 · TW
Monochromatic 222 nm UV light: Development of a safe, cost-effective technology for the efficient reduction of bacterial and viral infection and transmission
$500,000Sung-Jin Park · Eden Park Illumination, Inc. · R42 · FY2019 · AI
Novel Therapeutics for Pandemic and Epidemic Flu
$500,000Nexbio, Inc. · R43 · FY2004 · AI
VACCINE AND TREATMENT EVALUATION UNITS
$500,000David Bernstein · Cincinnati Childrens Hosp Med Ctr · N01 · FY2012 · AI
VACCINE AND TREATMENT EVALUATION UNITS
$500,000Patricia Winokur · University Of Iowa · N01 · FY2011 · AI
DEVELOPMENT OF A UNIVERSAL INFLUENZA VIRUS VACCINE
$500,000Peter Palese · Icahn School Of Medicine At Mount Sinai · RC1 · FY2009 · AI
A Novel Therapeutics for Pandemic &Epidemic Flu
$500,000Nexbio, Inc. · R43 · FY2005 · AI
Dose Optimization, Production & Tox Testing of Replicon-Vaccines for Smallpox
$500,000Robert A Olmsted · Alphavax Human Vaccines, Inc. · U01 · FY2009 · AI
The VAX-MOM study: Increasing Influenza and Tdap Vaccinations of Pregnant Women
$500,000Cynthia M Rand · University Of Rochester · U01 · FY2021 · IP
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** INFLUENZA IS ARGUABLY ONE OF THE MOST SIGNIFICANT DISEASES IN PIGS. BECAUSE VIRUS REASSORTMENT IS CENTRAL TO THE EMERGENCE OF NOVEL STRAINS DIFFICULT TO CONTROL AND CAUSE DISEASE IN PIGS AND PEOPLE, WE WILL INVESTIGATE FACTORS AT THE FARM LEVEL THAT DRIVE THE EMERGENCE OF NOVEL REASSORTANTS. WE HYPOTHESIZE THAT REASSORTMENT OF INFLUENZA IS A COMMON EVENT AND THAT THERE ARE FACTORS RELATED TO AGE, IMMUNITY AND PRODUCTION TYPE SYSTEM THAT DRIVE THE EMERGENCE OF REASSORTANT VIRUSES CAPABLE TO TRANSMIT AND CAUSE DISEASE. WE WILL FIRST IDENTIFY AND CHARACTERIZE INFLUENZA REASSORTANT VIRUSES IN INDIVIDUAL PIGS AND FARMS, AND THEN WE WILL EVALUATE WHETHER CERTAIN POPULATIONS OF PIGS, AND PRESENCE OF IMMUNITY (OR LACK OF) ARE RESPONSIBLE FOR THE EMERGENCE OF THE REASSORTANTS. WE EXPECT TO IDENTIFY AND QUANTIFY THE EXTENT OF REASSORTMENT HAPPENING IN THE PIGS AND DOCUMENT THAT YOUNG POPULATIONS THAT LACK PROTECTIVE IMMUNITY ARE LARGELY RESPONSIBLE FOR THE EMERGENCE OF REASSORTANT VIRUSES. ULTIMATELY, WE ANTICIPATE THAT WORK DERIVED FROM THIS STUDY WILL RESULT IN CHANGES IN MANAGEMENT PRACTICES AND VACCINATION PROTOCOLS THAT WILL HELP REDUCE THE EMERGENCE OF NOVEL REASSORTANTS IN PIGS RESULTING IN LESS ECONOMIC LOSSES TO PRODUCERS AND DECREASED RISK OF TRANSMISSION TO PEOPLE.
$500,000Regents Of The University Of Minnesota · · FY2022 · National Institute of Food and Agriculture
CAREER: An ImmunoBioEngineering Platform for Rapid and Scalable Biomanufacturing of Universal Viral Vaccines
$500,000Fei Wen · Regents Of The University Of Michigan - Ann Arbor · · FY2017 · ENG
THE ECONOMIC LOSSES RESULTING FROM SWINE INFLUENZA RANK AMONG THE TOP THREE HEALTH CHALLENGES TO THE PORK INDUSTRY. THE ABILITY OF COMMERCIALLY AVAILABLE INFLUENZA A VIRUS (IAV) VACCINES TO PROTECT PIGS AGAINST THIS VIRUS IS REDUCED DUE TO THE CONTINUOUS PROCESS OF ANTIGENIC VARIATION EXHIBITED BY INFLUENZA VIRUSES CIRCULATING IN COMMERCIAL PIG FARMS. THE AIM OF THIS PROJECT IS TO IMPROVE THE CAPABILITY OF CURRENT SWINE IAV VACCINES TO PROVIDE PROTECTION AGAINST A BROAD RANGE OF IAV VIRUSES. THIS WILL BE ACCOMPLISHED BY SUPPLEMENTING THE VACCINE WITH AN INVARIABLE VIRAL ANTIGEN SHARED BY ALL SUBTYPES OF IAV CURRENTLY CIRCULATING IN THE SWINE POPULATION, SPECIFICALLY THE MATRIX 2 (M2) PROTEIN. BECAUSE M2 IS SPARSELY PRESENT IN THE VIRUS, ORDINARY IAV VACCINES STIMULATE ONLY A MEAGER IMMUNE RESPONSE AGAINST THIS VIRAL PROTEIN. WE THEORIZE THAT BY SUPPLEMENTING CURRENT VACCINES WITH AN ADEQUATE AMOUNT OF M2, THE VACCINE WILL STIMULATE A STRONG IMMUNE RESPONSE TO THIS SHARED ANTIGEN. WE PREDICT THAT THE ADDITION OF M2 TO THE VACCINE WILL EXTEND THE RANGE OF PROTECTION PROVIDED BY A CONVENTIONAL VACCINE. SPECIFICALLY, IT WOULD PROTECT AGAINST THE IAV SUBTYPES INCLUDED IN THE VACCINE AND ALSO AGAINST ANTIGENIC VARIANTS THAT WOULD OTHERWISE ESCAPE VACCINE-INDUCED IMMUNITY. IMPROVING THE EFFICACY OF IAV VACCINES WILL RESULT IN IMPROVED SWINE HEALTH, HIGHER PROFITABILITY IN PORK PRODUCTION, AS WELL AS INCREASED FOOD SECURITY FOR THE AMERICAN PEOPLE.
$500,000University Of Illinois · · FY2020 · National Institute of Food and Agriculture
DEVELOPMENT OF A UNIVERSAL INFLUENZA VIRUS VACCINE
$500,000Peter Palese · Icahn School Of Medicine At Mount Sinai · RC1 · FY2010 · AI